ASMBR 2019

September 2019- Entera presented "An Evaluation of the Pharmacodynamic Effects of an Oral hPTH(1-34) formulation in Patients with Hypoparathyroidism" at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Orlando Florida. Hypoparathyroidism is characterized by deficient PTH production, hypocalcemia and Hyperphosphatemia. Entera presented results from a Phase 2, open-label, 2-period partial crossover study to evaluate the PK and PD profiles of two doses - 0.75 and 2.25 mg, and three regimens (BID, TID and QID) of Oral hPTH (1-34) and Natpara® [hPTH(1-84)]100 μg SC injection QD (the maximum approved dose).

pdfSee poster